Enasidenib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 72 min read
Enasidenib - Uses, Dosage, Side Effects, Interaction
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

On this page10 sections

Article Summary

Enasidenib is an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells....

Key Takeaways

  • This article explains Mechanism of action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Definition

Enasidenib is an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.

Enasidenib is an orally available small molecule inhibitor of isocitrate dehydrogenase and antineoplastic agent that is used in the therapy of selected cases of myeloid (AML). Enasidenib is associated with a rate of serum aminotransferase elevations during therapy and rare instances of clinically apparent acute injury.

Enasidenib is a 1,3,5-triazine that is substituted by (2-hydroxy-2-methyl propyl)nitrilo, 6-(trifluoromethyl)pyridine-2-yl and [2-(trifluoromethyl)pyridin-4-yl]nitrilo groups at positions 2,4 and 6, respectively. It is an isocitrate dehydrogenase-2 (IDH2) inhibitor that has been approved for the treatment of adults with relapsed or acute myeloid leukemia (AML). It has a role as an antineoplastic agent and an EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor. It is an aminopyridine, an organofluorine compound, a secondary amino compound, a tertiary alcohol, a member of 1,3,5-triazines, and an aromatic amine.

Enasidenib Mesylate is the mesylate salt form of enasidenib, an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.

Mechanism of action

Enasidenib is a selective inhibitor of IDH2, a mitochondria- enzyme involved in diverse cellular processes, including adaptation to , histone demethylation, and DNA modification [rx]. Wild-type IDH proteins play a crucial role in the Krebs/citric acid cycle where it catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate. In comparison, mutant forms of IDH2 enzyme mediate a neomorphic activity and catalyze the reduction of α-KG to the (R) enantiomer of 2-hydroxyglutarate, which is associated with DNA and histone hypermethylation, altered gene expression, and blocked cellular differentiation of hematopoietic progenitor cells ]rx]. Enasidenib primarily targets the mutant IDH2 variants R140Q, R172S, and R172K with higher potency than the wild-type enzyme form. Inhibition of the enzyme leads to decreased levels of 2-hydroxyglutarate (2-HG) and the promotion of proper differentiation and clonal proliferation of cells of the myeloid lineage [rx].

In a study involving adult patients with relapsed or refractory AML, the overall response rate of 40.3% was achieved in enasidenib therapy which was associated with cellular differentiation and maturation, typically without evidence of aplasia [rx]. Enasidenib is not shown to cause QTc prolongation.

Indications

  • Indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.
  • Treatment of acute myeloid
  • Enasidenib is an orally available small molecule inhibitor of isocitrate dehydrogenase and antineoplastic agent that is used in the therapy of selected cases of acute myeloid leukemia (AML).
  • Enasidenib is used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the IDH2 gene, determined by an FDA-approved IDH2 companion diagnostic test.[rx]
  • Refractory Acute Myeloid Leukemia (AML)
  • Relapsed Acute Myelogenous Leukemia (AML)

Contraindications

  • high levels of white blood cells
  • the high amount of in the blood
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • a of treatment in certain types of leukemia called differentiation

Strengths: 50 mg; 100 mg

Acute Myeloid Leukemia

  • 100 mg orally once a day with or without food
  • Duration of Therapy: Treat until or unacceptable toxicity.
  • For patients without disease or unacceptable toxicity, treatment for a minimum of 6 months to allow time for response.

Select patients based on the presence of isocitrate dehydrogenase-2 (IDH2) mutations in the blood or as detected by an FDA-approved test, http://www.fda.gov/CompanionDiagnostics. Treatment of relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation.

Dose Adjustments

MANAGING TOXICITIES:
Differentiation Syndrome:

  • If differentiation syndrome is suspected, administer corticosteroids and initiate hemodynamic .
  • Interrupt treatment if pulmonary symptoms requiring intubation or ventilator support, and/or dysfunction persist for more than 48 hours after initiation of corticosteroids.
  • Resume treatment when signs/symptoms improve to Grade 2 or lower.

Noninfectious [white blood cell (WBC) count greater than 30 x 10(9)/L]:

  • Initiate hydroxyurea, as per standard institutional practices.
  • Interrupt enasidenib if leukocytosis is not improved with hydroxyurea, and then resume enasidenib at 100 mg daily when WBC is less than 30 x 10(9)/L.

Other Treatment-Related Grade 3 or Higher Toxicity (e.g., tumor lysis syndrome):

  • Interrupt treatment until toxicity resolves to Grade 2 or lower.
  • Resume treatment at 50 mg/day; may increase to 100 mg/day if toxicities resolve to Grade 1 or lower.
  • Discontinue treatment if Grade 3 or higher toxicity recurs.

Side Effects

The Most Common

  • decreased appetite
  • change in the way things taste
  • yellowing of your eyes or skin
  • muscle spasms or twitching; burning, prickling, or feeling on the skin; irregular heartbeat; or seizures
  • , , trouble breathing;
  • bone pain;
  • rapid weight gain; or
  • swelling in your arms, legs, underarms, groin, or neck.
  • severe or ongoing vomiting or diarrhea; or
  • signs of tumor cell breakdown–tiredness, weakness, muscle cramps, nausea, vomiting, diarrhea, fast or slow heart rate, tingling in your hands and feet or around your mouth.
  • dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
  • loss of appetite; or
  • jaundice.
  • nausea, vomiting, diarrhea;

More common

  • Agitation
  • blue lips, fingernails, or skin
  • bone pain
  • chest pain
  • chills
  • confusion
  • cough
  • coughing that sometimes produces a pink frothy sputum
  • decreased awareness or responsiveness
  • decreased urine output
  • depression
  • difficult or troubled breathing
  • difficult, fast, noisy breathing
  • dizziness
  • eye pain
  • fainting
  • fast heartbeat
  • fever
  • a general feeling of illness
  • headache
  • hostility
  • increased sweating
  • irregular, fast or slow, or shallow breathing
  • irritability
  • lightheadedness
  • loss of consciousness
  • muscle or joint pain
  • muscle twitching
  • nausea
  • pale skin
  • rapid weight gain
  • rapid, shallow breathing
  • seizures
  • severe sleepiness
  • sore throat
  • swelling around the neck, groin, or underarm area
  • swelling of the arms, feet, or lower legs
  • swelling of the face, ankles, or hands
  • unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
  • yellow skin or eyes

Rare

  • changed sense of taste
  • decreased appetite
  • diarrhea
  • fatigue
  • nausea
  • vomiting
  • difficulty breathing at rest or worsens when lying down
  • fever
  • signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath)
  • signs of clotting problems (e.g., unusual nosebleeds, bruising, blood in urine, coughing blood, bleeding gums, cuts that don’t stop bleeding)
  • signs of infection (e.g., fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness)
  • signs of liver problems (e.g., nausea, vomiting, diarrhea, loss of appetite, weight loss, yellowing of the skin or whites of the eyes, dark urine, pale stools)
  • low levels of oxygen (hypoxia; changes in skin color, confusion, fast heart rate, rapid breathing, shortness of breath, sweating, wheezing)
  • symptoms of differentiation syndrome (e.g., fever, cough, shortness of breath, arm, leg, or neck swelling, fast weight gain, dizziness, lightheadedness, bone pain)
  • symptoms of tumor lysis syndrome (e.g., producing less urine, cloudy urine, kidney problems, muscle spasms, nausea, shortness of breath)

Drug Interactions

Drug-Food Interactions

  • Exercise caution with grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of enasidenib; however, CYP3A4 is one of many enzymes involved in enasidenib metabolism.
  • Exercise caution with St. John’s Wort. This herb induces CYP3A4 metabolism, which may reduce the serum concentration of enasidenib; however, CYP3A4 is one of many enzymes involved in enasidenib metabolism.
  • Take it at the same time every day.
  • Take it with a full glass of water.
  • Take it with or without food.

Pregnancy And Lactation

US FDA pregnancy category Not Assigned:

Pregnancy

Based on animal embryo-fetal toxicity studies, IDHIFA can cause fetal harm when administered to a pregnant woman. There are no available data on IDHIFA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. In animal embryo-fetal toxicity studies, oral administration of enasidenib to pregnant rats and rabbits during organogenesis was associated with embryo-fetal mortality and alterations to growth starting at 0.1 times the steady-state clinical exposure based on the AUC at the recommended human dose (see Data). If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, advise the patient of the potential risk to a fetus. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively.

Lactation

No information is available on the clinical use of enasidenib during breastfeeding. Because enasidenib is 98.5% bound to plasma proteins and its active metabolite is 96.6% bound to plasma proteins, the amount in milk is likely to be low. However, the half-life of enasidenib is 137 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during enasidenib therapy and for at least 2 months after the end of therapy.

How should this medicine be used?

Enasidenib comes as a tablet to take by mouth. It is usually taken once a day with or without food. Take enasidenib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take enasidenib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the tablets whole with a cup (8 ounces [240 mL]) of water; do not split, chew, or crush them.

If you vomit after taking a dose of enasidenib, take another dose as soon as possible on the same day.

Your doctor may temporarily or permanently stop your treatment, decrease your dose of enasidenib, or treat you with other medications depending on the side effects that you experience. Be sure to talk to your doctor about how you are feeling during your treatment. Do not stop taking enasidenib without talking to your doctor.

What special precautions should I follow?

Before taking enasidenib,

  • tell your doctor and pharmacist if you are allergic to enasidenib, any other medications, or any of the ingredients in enasidenib tablets. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. You should not become pregnant while you are taking enasidenib. You will need to have a negative pregnancy test before you begin taking this medication. Use effective birth control during your treatment with enasidenib and for one month after your final dose. If you are a male and your partner can become pregnant, you should use effective birth control during your treatment and for one month after your final dose. Enasidenib may decrease the effectiveness of certain oral contraceptives so talk to your doctor about birth control methods that will work for you. If you or your partner become pregnant while taking enasidenib, call your doctor.
  • tell your doctor if you are breastfeeding. You should not breastfeed while you are enasidenib and for one month after your final dose.
  • you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of taking enasidenib.
References

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf
  2. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-granted-regular-approval-enasidenib-treatment-relapsed-or-refractory-aml
  3. https://pubchem.ncbi.nlm.nih.gov/compound/Enasidenib
  4. https://pubchem.ncbi.nlm.nih.gov/compound/Enasidenib-mesylate
  5. https://www.webmd.com/drugs/2/drug-173965/enasidenib-oral/details/list-contraindications
  6. https://www.mayoclinic.org/drugs-supplements/enasidenib-oral-route/precautions/drg-20406484?p=1
  7. https://medlineplus.gov/druginfo/meds/a617040.html
  8. https://www.drugs.com/mtm/enasidenib.html
  9. https://en.wikipedia.org/wiki/Enasidenib
  10. https://go.drugbank.com/drugs/DB13874
  11. CAS Common Chemistry
    https://creativecommons.org/licenses/by-nc/4.0/
    https://commonchemistry.cas.org/detail?cas_rn=1446502-11-9
  12. ChemIDplus
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    Enasidenib [USAN:INN]
    https://chem.nlm.nih.gov/chemidplus/sid/1446502119
    AG 221
    https://chem.nlm.nih.gov/chemidplus/sid/1802003093
    ChemIDplus Chemical Information Classification
    https://chem.nlm.nih.gov/chemidplus/
  13. DrugBank
    https://www.drugbank.ca/legal/terms_of_use
    Enasidenib
    https://www.drugbank.ca/drugs/DB13874
  14. EPA DSSTox
    LICENSE
    https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
    Enasidenib
    https://comptox.epa.gov/dashboard/DTXSID801027942
    CompTox Chemicals Dashboard Chemical Lists
    https://comptox.epa.gov/dashboard/chemical-lists/
  15. FDA Global Substance Registration System (GSRS)
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    ENASIDENIB
    https://gsrs.ncats.nih.gov/ginas/app/beta/substances/3T1SS4E7AG
  16. ChEBI
    Enasidenib
    http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:145374
    ChEBI Ontology
    http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
  17. FDA Pharm Classes
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    ENASIDENIB
    https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm
    FDA Pharmacological Classification
    https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
  18. LiverTox
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    Enasidenib
    https://www.ncbi.nlm.nih.gov/books/n/livertox/Enasidenib/
  19. NCI Thesaurus (NCIt)
    https://www.cancer.gov/policies/copyright-reuse
    https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C111573
    NCI Thesaurus Tree
    https://ncit.nci.nih.gov
  20. ClinicalTrials.gov
    https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
    https://clinicaltrials.gov/
  21. Drug Gene Interaction database (DGIdb).
    http://www.dgidb.org/downloads
    ENASIDENIB
    https://www.dgidb.org/drugs/ENASIDENIB
  22. IUPHAR/BPS Guide to PHARMACOLOGY
    https://www.guidetopharmacology.org/about.jsp#license
    enasidenib
    https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8960
    Guide to Pharmacology Target Classification
    https://www.guidetopharmacology.org/targets.jsp
  23. Therapeutic Target Database (TTD)
    AG-221
    http://idrblab.net/ttd/data/drug/details/D0K7FT
  24. European Medicines Agency (EMA)
    https://www.ema.europa.eu/en/about-us/legal-notice
    Enasidenib (P/0293/2017)
    https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001798-pip02-16
  25. Drugs and Lactation Database (LactMed)
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    Enasidenib
    https://www.ncbi.nlm.nih.gov/books/NBK500925/
  26. EU Clinical Trials Register
    https://www.clinicaltrialsregister.eu/
  27. FDA Orange Book
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  28. FDA Medication Guides
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    Idhifa
    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=medguide.page
  29. Human Metabolome Database (HMDB)
    http://www.hmdb.ca/citing
    Enasidenib
    http://www.hmdb.ca/metabolites/HMDB0251786
  30. NLM RxNorm Terminology
    https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
    enasidenib
    https://rxnav.nlm.nih.gov/id/rxnorm/1940332
  31. Protein Data Bank in Europe (PDBe)
    http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/69Q
  32. RCSB Protein Data Bank (RCSB PDB)
    https://www.rcsb.org/pages/policies
    https://www.rcsb.org/
  33. Springer Nature
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=33061531-801899220
  34. Thieme Chemistry.
    https://creativecommons.org/licenses/by-nc-nd/4.0/
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=33061531-801899220
  35. WHO Anatomical Therapeutic Chemical (ATC) Classification
    https://www.whocc.no/copyright_disclaimer/
    https://www.whocc.no/atc/
    ATC Code
    https://www.whocc.no/atc_ddd_index/
  36. Wikidata
    LICENSE
    CCZero
    https://creativecommons.org/publicdomain/zero/1.0/
    Enasidenib
    https://www.wikidata.org/wiki/Q27077182
  37. PubChem
    https://pubchem.ncbi.nlm.nih.gov
    PFAS and Fluorinated Compounds in PubChem
    https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false
  38. Medical Subject Headings (MeSH)
    https://www.nlm.nih.gov/copyright.html
    enasidenib
    https://www.ncbi.nlm.nih.gov/mesh/2011767
    MeSH Tree
    http://www.nlm.nih.gov/mesh/meshhome.html
  39. KEGG
    https://www.kegg.jp/kegg/legal.html
    Anatomical Therapeutic Chemical (ATC) classification
    http://www.genome.jp/kegg-bin/get_htext?br08303.keg
    Target-based classification of drugs
    http://www.genome.jp/kegg-bin/get_htext?br08310.keg
  40. ChEMBL
    http://www.ebi.ac.uk/Information/termsofuse.html
    ChEMBL Protein Target Tree
    https://www.ebi.ac.uk/chembl/g/#browse/targets
  41. NORMAN Suspect List Exchange
    https://creativecommons.org/licenses/by/4.0/
    NORMAN Suspect List Exchange Classification
    https://www.norman-network.com/nds/SLE/
  42. National Drug Code (NDC) Directory
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    FDA Drug Type and Pharmacologic Classification
    https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
  43. PATENTSCOPE (WIPO)
    SID 393443194
    https://pubchem.ncbi.nlm.nih.gov/substance/393443194

RX Medical Knowledge Graph

Explore this medical topic

Continue through verified related conditions, investigations, medicines, and patient guides. These links are educational and do not replace professional medical advice.

Related medical topics

COVID‑19 Vaccine - Uses, Dosage, Side Effects, Interactions83% relationship confidence Dosage of Filgrastim - Side Effects, Interaction83% relationship confidence Estrogen Drug - Uses, Dosage, Side Effects, Interaction83% relationship confidence Filgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Influenza Vaccines - Uses, Dosage, Side Effect, Interaction83% relationship confidence Lipegfilgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Meropenem - Uses, Dosage, Side Effects, Interactions83% relationship confidence What Is Antacids? -Uses, Dosage, Side Effects, Interaction83% relationship confidence
More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia?, Pain? Associated With Fibromyalgia?, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)
RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Enasidenib – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.